ChemoRad nanoparticles: a novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation.
OBJECTIVE
The development of chemoradiation - the concurrent administration of chemotherapy and radiotherapy - has led to significant improvements in local tumor control and survival. However, it is limited by its high toxicity. In this study, we report the development of a novel NP (nanoparticle) therapeutic, ChemoRad NP, which can deliver biologically targeted chemoradiation.


METHODS
A biodegradable and biocompatible lipid-polymer hybrid NP that is capable of delivering both chemotherapy and radiotherapy was formulated.


RESULTS
Using docetaxel, indium(111) and yttrium(90) as model drugs, we demonstrated that the ChemoRad NP can encapsulate chemotherapeutics (up to 9% of NP weight) and radiotherapeutics (100 mCi of radioisotope per gram of NP) efficiently and deliver both effectively. Using prostate cancer as a disease model, we demonstrated the targeted delivery of ChemoRad NPs and the higher therapeutic efficacy of ChemoRad NPs.


CONCLUSIONS
We believe that the ChemoRad NP represents a new class of therapeutics that holds great potential to improve cancer treatment.
Wang
Andrew Z
AZ
Laboratory of Nanomedicine & Biomaterials, Department of Anesthesia, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA. ofarokhzad@partners.org
Yuet
Kai
K
Zhang
Liangfang
L
Gu
Frank X
FX
Huynh-Le
Minh
M
Radovic-Moreno
Aleksandar F
AF
Kantoff
Philip W
PW
Bander
Neil H
NH
Langer
Robert
R
Farokhzad
Omid C
OC
D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000494:pharmacology; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D003131:Combined Modality Therapy; D000077143:Docetaxel; D006801:Humans; D007205:Indium Radioisotopes / Q000008:administration & dosage* / Q000494:pharmacology; D008297:Male; D053758:Nanoparticles / Q000737:chemistry* / Q000648:ultrastructure; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy*; D043823:Taxoids / Q000008:administration & dosage* / Q000494:pharmacology; D015021:Yttrium Radioisotopes / Q000008:administration & dosage* / Q000494:pharmacology
D000970:Antineoplastic Agents; D007205:Indium Radioisotopes; D043823:Taxoids; D015021:Yttrium Radioisotopes; D000077143:Docetaxel
Langmuir. 2005 Sep 13;21(19):8852-7
16142970
Cancer Res. 1996 May 1;56(9):2123-9
8616860
Expert Rev Anticancer Ther. 2006 Mar;6(3):445-61
16503861
Br J Cancer. 1991 Dec;64(6):1125-32
1764376
Lancet. 1987 Sep 12;2(8559):624-5
2887906
Cancer Res. 2006 Jul 1;66(13):6732-40
16818648
Nano Lett. 2009 May;9(5):1909-15
19344179
Pharm Res. 2005 Dec;22(12):2107-14
16254763
Semin Nucl Med. 1989 Jul;19(3):187-201
2503873
ChemMedChem. 2007 Sep;2(9):1268-71
17600796
Cancer Res. 2002 Jul 15;62(14):4029-33
12124337
ACS Nano. 2008 Aug;2(8):1696-702
19206374
Expert Opin Drug Deliv. 2008 Apr;5(4):371-83
18426380
J Control Release. 2000 Mar 1;65(1-2):271-84
10699287
Proc Natl Acad Sci U S A. 2006 Apr 18;103(16):6315-20
16606824
Angew Chem Int Ed Engl. 2006 Dec 11;45(48):8149-52
17099918
J Control Release. 2004 Mar 24;95(3):613-26
15023471
ChemMedChem. 2008 Sep;3(9):1311-5
18613203
Int J Pharm. 2007 Sep 5;342(1-2):208-14
17560058
Nano Lett. 2007 Oct;7(10):3065-70
17854227
Nat Clin Pract Oncol. 2007 Feb;4(2):86-100
17259930
Nat Protoc. 2006;1(1):314-7
17406251
Cancer Res. 2004 Nov 1;64(21):7668-72
15520166
Cancer Biother Radiopharm. 2003 Feb;18(1):99-107
12667313